EP Patent

EP4014970A1 — A solid oral composition of eltrombopag olamine

Assigned to Genepharm SA · Expires 2022-06-22 · 4y expired

What this patent protects

A solid oral composition comprising 5-40% by weight of 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) and at least one excipient; wherein the composition is prepared b…

USPTO Abstract

A solid oral composition comprising 5-40% by weight of 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) and at least one excipient; wherein the composition is prepared by direct compression.

Drugs covered by this patent

Patent Metadata

Patent number
EP4014970A1
Jurisdiction
EP
Classification
—
Expires
2022-06-22
Drug substance claim
No
Drug product claim
No
Assignee
Genepharm SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.